Wall Street brokerages expect Clovis Oncology (NASDAQ:CLVS) to report sales of $17.50 million for the current quarter, according to Zacks. Four analysts have made estimates for Clovis Oncology’s earnings, with estimates ranging from $17.00 million to $18.30 million. Clovis Oncology posted sales of $7.05 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 148.2%. The firm is scheduled to issue its next quarterly earnings report on Wednesday, May 2nd.
According to Zacks, analysts expect that Clovis Oncology will report full year sales of $146.53 million for the current year, with estimates ranging from $112.00 million to $173.30 million. For the next year, analysts forecast that the firm will report sales of $327.11 million per share, with estimates ranging from $245.00 million to $403.53 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Clovis Oncology.
Clovis Oncology (NASDAQ:CLVS) last posted its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.29) by $0.25. The company had revenue of $17.04 million during the quarter, compared to analyst estimates of $19.42 million. Clovis Oncology had a negative net margin of 624.02% and a negative return on equity of 81.34%. The company’s revenue was up 21746.2% on a year-over-year basis. During the same quarter last year, the business posted ($1.83) earnings per share.
In other Clovis Oncology news, insider Gillian C. Ivers-Read sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $54.09, for a total value of $162,270.00. Following the transaction, the insider now directly owns 180,571 shares of the company’s stock, valued at $9,767,085.39. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Thorlef Spickschen sold 4,500 shares of the firm’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $60.00, for a total transaction of $270,000.00. Following the completion of the transaction, the director now directly owns 16,618 shares in the company, valued at $997,080. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 19,500 shares of company stock worth $1,156,455. Insiders own 12.50% of the company’s stock.
A number of hedge funds have recently made changes to their positions in CLVS. Russell Investments Group Ltd. boosted its stake in Clovis Oncology by 455.1% in the third quarter. Russell Investments Group Ltd. now owns 34,425 shares of the biopharmaceutical company’s stock valued at $2,836,000 after acquiring an additional 28,223 shares during the last quarter. Legal & General Group Plc boosted its stake in Clovis Oncology by 14.5% in the third quarter. Legal & General Group Plc now owns 17,962 shares of the biopharmaceutical company’s stock valued at $1,476,000 after acquiring an additional 2,269 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its stake in Clovis Oncology by 10.7% in the third quarter. Schwab Charles Investment Management Inc. now owns 209,894 shares of the biopharmaceutical company’s stock valued at $17,296,000 after acquiring an additional 20,267 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Clovis Oncology by 62.4% in the third quarter. Dimensional Fund Advisors LP now owns 40,391 shares of the biopharmaceutical company’s stock valued at $3,328,000 after acquiring an additional 15,525 shares during the last quarter. Finally, First Republic Investment Management Inc. bought a new position in Clovis Oncology in the third quarter valued at approximately $251,000.
NASDAQ CLVS opened at $60.64 on Friday. The company has a market cap of $3,155.77, a PE ratio of -11.84 and a beta of 0.93. The company has a debt-to-equity ratio of 0.77, a current ratio of 7.69 and a quick ratio of 7.35. Clovis Oncology has a 1-year low of $45.42 and a 1-year high of $99.45.
COPYRIGHT VIOLATION NOTICE: “$17.50 Million in Sales Expected for Clovis Oncology (CLVS) This Quarter” was reported by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://dakotafinancialnews.com/2018/04/14/17-50-million-in-sales-expected-for-clovis-oncology-clvs-this-quarter.html.
Clovis Oncology Company Profile
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.